Baxter Class Action Lawsuit (BAX)
A shareholder case over alleged infusion pump defects, with a class period running more than three and a half years. If you are here about an injury rather than a stock loss, this is not your case.
Active litigation. There is no claim form and no payout yet.
| Company | Baxter International Inc. (NYSE: BAX) |
|---|---|
| First complaint filed | 16 October 2025 |
| Class period | 23 February 2022 – 29 October 2025 (a parallel action pleads 23 February 2022 – 30 July 2025) |
| Claims | §10(b) and §20(a), Securities Exchange Act of 1934 |
| Lead plaintiff deadline | 15 December 2025 — passed, and it does not affect your recovery |
| Can you file a claim? | Not yet. Realistically 2029 or later if the case settles. |
This page covers the securities case — a lawsuit by shareholders who bought BAX stock, alleging the company misled investors about a product problem. Recovery goes to investors, based on stock losses.
If you were injured by a Baxter infusion pump, that is a personal injury and product liability matter, not this case. Different claim, different court, different lawyer, different measure of damages. Nothing on this page applies to you — speak to a medical device injury attorney directly.
Who the securities case covers
Anyone who purchased or otherwise acquired Baxter International common stock between 23 February 2022 and 29 October 2025.
That is a long class period — more than three and a half years — which means it captures a very large number of holders, including most people who held BAX through a retirement or index-adjacent account during that window. Competing complaints plead slightly different end dates (30 July 2025 versus 29 October 2025); the consolidated complaint filed by court-appointed lead counsel will settle which window governs.
What the case alleges
The complaints allege that Baxter and certain current and former officers made materially false and misleading statements and failed to disclose that:
- ✓the Novum IQ large volume pump (LVP) suffered systemic defects producing widespread malfunctions — including underinfusion, overinfusion, and complete failure to deliver fluids;
- ✓those malfunctions exposed patients to risk of serious injury or death;
- ✓Baxter had been notified of multiple device malfunctions, injuries, and deaths arising from the defects; and
- ✓Baxter's response — customer alerts and field notifications — was inadequate as a remedial measure.
These are allegations. Baxter denies wrongdoing and the case has not been tested on a motion to dismiss.
Why this case is being watched closely
Securities cases built on top of a regulated product safety problem tend to be more durable than the average stock-drop suit, because the underlying facts are partly documented in an independent public record — device malfunction reporting, recall classifications, and regulator correspondence — rather than resting on inference from a share price chart. That does not make the case a winner, but it does make it less likely to be disposed of quickly at the pleading stage.
It also means the securities case and any product liability litigation will develop in parallel and feed each other. Watch the device regulatory track for the leading indicator.
What to do now
- ✓Preserve your BAX trade confirmations covering 2022 onward. This is the most important practical step and the one most people fail. The class period opens in February 2022; by the time a claim form exists that is likely to be seven-plus years back, right at the edge of standard brokerage record retention. Download the statements now.
- ✓You do not need to do anything else. Securities class actions are opt-out — if you bought in the class period you are already a class member. No retainer, no signup, no fee.
- ✓Set an alert for the claim window.
Frequently Asked Questions
I missed the 15 December 2025 deadline. Is my claim gone?
No. That was the lead plaintiff deadline — it decided only who directs the case. Your right to recover is untouched.
I held BAX in a 401(k) or index fund. Am I covered?
The shareholder of record is whoever holds the shares. Plan custodians and fund managers typically file claims on behalf of the assets they hold, and the benefit flows to the fund. For a directly held brokerage or IRA position, filing is your responsibility.
I was harmed by one of the pumps. Can I use this case?
No. Personal injury claims are entirely separate from this securities action and are not covered by any recovery here. Speak to a medical device injury attorney.
Does the length of the class period mean a bigger payout for me?
Not directly. A longer class period means more claimants sharing the same fund. What determines your individual share is the size and timing of your own purchases relative to the alleged price inflation.
How much will shareholders recover?
Unknown. No settlement exists. Securities settlements historically return a modest percentage of claimed damages, and the figure depends on the strength of the case, the provable inflation in the share price, and available insurance.
See every settlement you qualify for
Tell SettleScout which brands you use and it matches you with open settlements, estimates your payouts, and reminds you before every deadline.
Free to download. Premium plans available.